# Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

> **NCT07340164** · PHASE2 · RECRUITING · sponsor: **Yonsei University** · enrollment: 116 (estimated)

## Conditions studied

- Ovarian Cancer
- Ovarian Carcinoma, Recurrent
- Ovarian Cancer Metastatic Recurrent
- Ovarian Cancer (OvCa)

## Interventions

- **DRUG:** Trastzumab Deruxtecan
- **DRUG:** Bevacizumab
- **DRUG:** Platinum Based Chemotherapy

## Key facts

- **NCT ID:** NCT07340164
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2026-12-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07340164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07340164, "Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07340164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*